AVROBIO Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
TECX$21.97+0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(amounts in thousands)
| Common Stock · AdditionalPaid-in · Accumulated · TotalStockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance as of December 31, 2021 | 43,652 | $4 | $553,014 | $(383,542) | $169,476 |
| Vesting of restricted stock awards and units | 1 | — | — | — | — |
| Exercise of stock options | 142 | — | 58 | — | 58 |
| Issuance of common stock under 2018 employee stock purchase plan | 121 | — | 204 | — | 204 |
| Stock-based compensation expense | — | — | 11,522 | — | 11,522 |
| Net loss | — | — | — | (105,890) | (105,890) |
| Balance as of December 31, 2022 | 43,916 | 4 | 564,798 | (489,432) | 75,370 |
| Vesting of restricted stock units | 306 | — | — | — | — |
| Exercise of stock options | 298 | — | 235 | — | 235 |
| Issuance of common stock under 2018 employee stock purchase plan | 134 | — | 86 | — | 86 |
| Stock-based compensation expense | — | — | 6,891 | — | 6,891 |
| Net loss | — | — | — | 12,157 | 12,157 |
| Balance as of December 31, 2023 | 44,654 | $4 | $572,010 | $(477,275) | $94,739 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.